Equity Details
Price & Market Data
Price: $11.39
Daily Change: -$0.15 / 1.32%
Daily Range: $11.14 - $11.51
Market Cap: $1,556,707,456
Daily Volume: 468,310
Performance Metrics
1 Week: 4.02%
1 Month: 4.78%
3 Months: 14.70%
6 Months: 25.86%
1 Year: 149.8%
YTD: 8.48%
About Immatics N.V. (IMTX)
Comprehensive analysis of Immatics N.V. (IMTX). Currently at 11.39, with a daily change of -$0.15 / 1.32%. Market cap: 1,556,707,456. Evaluate its performance over YTD, 1-month, and 6-month periods.
Company Details
Employees: 407
Sector: Health technology
Industry: Pharmaceuticals: major
Country: Germany
Details
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.